Recently, pemigatinib, an FGFR2 inhibitor used in patients with FGFR2-rearranged cholangiocarcinoma, received FDA approval for relapsed/refractory myeloid and/or lymphoid neoplasms with FGFR1 rearrangements. Here, FGFR1 is linked to lymphoid neoplasm.